-
公开(公告)号:US20160257710A1
公开(公告)日:2016-09-08
申请号:US15032655
申请日:2014-11-04
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA RECHERCHE MÉDICALE) , UNIVERSITE DE TOURS FRANCOIS RABELAIS , UNIWERSYTET GDANSKI
发明人: Francis GAUTHIER , Brice KORKMAZ , Adam LESNER
IPC分类号: C07K5/113 , G01N33/573 , C07K5/103 , A61K47/48 , C07K5/117
CPC分类号: C07K5/1021 , A61K38/00 , A61K47/545 , A61K47/60 , C07K5/0808 , C07K5/0819 , C07K5/0823 , C07K5/101 , C07K5/1024 , G01N33/573
摘要: The present invention relates to peptidyl phosphonate esters compounds and their use selective inhibitors of proteinase 3, in particular for treating or diagnosing inflammator autoimmune and cancer disorders. More specifically, the invention concerns nov peptidyl phosphonate esters compounds, including without limitation, compounds with Asp-Tyr-Asp-Ala or Pro-Tyr-Asp-Ala, Pro-Tyr-Asp-Avl, Val-Tyr-Asp-Avl peptide structure or their derivatives.
摘要翻译: 本发明涉及肽基膦酸酯化合物及其使用蛋白酶3的选择性抑制剂,特别是用于治疗或诊断炎症自身免疫和癌症疾病。 更具体地说,本发明涉及Nov肽基膦酸酯化合物,包括但不限于Asp-Tyr-Asp-Ala或Pro-Tyr-Asp-Ala,Pro-Tyr-Asp-Avl,Val-Tyr-Asp-Avl肽 结构或其衍生物。